Lipocine Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LPCN research report →
Range $4 – $6
Price Chart
About the company
Lipocine Inc. is a biopharmaceutical firm currently in the clinical development phase, concentrating its efforts on creating medicinal products to address a range of neuroendocrine and metabolic conditions. A core aspect of the company's research and development involves formulating oral delivery methods for pharmaceutical compounds that typically suffer from low bioavailability.
- CEO
- Mahesh V. Patel
- IPO
- 2013
- Employees
- 14
- HQ
- Salt Lake City, UT, US
Get TickerSpark's AI analysis on LPCN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $17.31M
- P/E
- -1.12
- PEG
- 0.01
- P/S
- 11.03
- P/B
- 0.79
- EV/EBITDA
- -1.05
- Div Yield
- 0.00%
- Gross Margin
- 98.10%
- Op Margin
- -800.82%
- Net Margin
- -755.13%
- ROE
- -64.75%
- ROIC
- -57.74%
Latest fiscal year · YoY change
- Revenue
- $1.98M-82.3%
- Gross Profit
- $-6,607,242-159.0%
- Op Income
- $-10,371,379
- Net Income
- $-9,627,505-115371.9%
- EPS
- $-1.77-110725.0%
- OCF Growth
- -699.3%
- FCF Growth
- -644.3%
- 52W High
- $12.37
- 52W Low
- $1.81
- 50D MA
- $2.16
- 200D MA
- $4.40
- Beta
- 0.47
- RSI (14)
- 45
- Avg Volume
- 35.43K
No earnings-call transcripts are available for LPCN yet.
- Free Float
- 95.5%
- Shares Outstanding
- 8.24M
- Float Shares
- 7.87M
of shares held by institutions
46 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Squadron Capital Management LLC | 810.00K | ▲ 360.00K |
| Ikarian Capital, LLC | 508.56K | 0 |
| Eversept Partners, LP | 294.99K | 0 |
| Vanguard Capital Management LLC | 230.82K | ▲ 30.16K |
| Vanguard Group Inc | 221.87K | 0 |
| Acadian Asset Management LLC | 170.42K | ▲ 170.42K |
| Boothbay Fund Management, LLC | 140.49K | 0 |
| Jane Street Group, LLC | 95.23K | ▲ 75.20K |
| Blackrock, Inc. | 89.27K | 0 |
| Two Sigma Investments, LP | 84.89K | ▲ 51.14K |
| Citadel Advisors LLC | 81.22K | ▲ 52.13K |
| Seven Fleet Capital Management LP | 78.84K | ▼ 46.10K |
Held by 26 ETFs
Biggest fund positions in LPCN by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 30, 26 | Higuchi John W. | buy | 15,970 |
| Sep 29, 26 | Higuchi John W. | buy | 9,037 |
| Sep 28, 26 | Higuchi John W. | buy | 12,561 |
| Aug 3, 26 | Grissinger Michael | other | 2,000 |
| Aug 3, 26 | Grissinger Michael | other | 0 |
| Jun 29, 26 | Patel Mahesh V. | other | 52,781 |
| Jun 3, 26 | Higuchi John W. | other | 1,764 |
| Jun 3, 26 | Jene Jill M. | other | 1,764 |
| Jun 3, 26 | Ono Richard Dana | other | 1,764 |
| Apr 7, 26 | Higuchi John W. | buy | 40,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our LPCN coverage
Recent articles, reports, and earnings notes.
No research on LPCN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate LPCN report →Lipocine (LPCN) Upgraded to Buy: What Does It Mean for the Stock?
zacks.com · Sep 23
Lipocine Announces Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression
prnewswire.com · Sep 14
Lipocine to Present at the H.C. Wainwright 28th Annual Global Investment Conference
prnewswire.com · Sep 10
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2026
prnewswire.com · Aug 4
Lipocine Appoints Michael J. Grissinger to Board of Directors
prnewswire.com · Aug 3
Lipocine Inc. to Host Virtual KOL Event Highlighting Unmet Needs in Postpartum Depression and the Clinical Profile of LPCN 1154
prnewswire.com · Jun 4
Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting
prnewswire.com · May 19
Anaveon Strengthens Leadership Team with Appointments of Eric Zanelli as Chief Scientific Officer and Jill Jene as Chief Business Officer
globenewswire.com · May 19
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.